SCHEMBL1726474

SCHEMBL1726474

O=C(Nc1nc(-c2ccccn2)cs1)c1ccc(S(=O)(=O)C2CCc3ccccc3N2)cc1F

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 6/20 0.53
KDM4A O75164 4/20 0.46
KDM4B O94953 4/20 0.46
KDM5B Q9UGL1 4/20 0.46
KDM5C P41229 2/20 0.46
MITF O75030 1/20 0.46
SLC2A1 P11166 2/20 0.46
GRM1 Q13255 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
USP2 O75604 1/20 0.45
ALOX15 P16050 1/20 0.45
MAPK1 P28482 1/20 0.45
ADORA3 P0DMS8 2/20 0.45
NCOA1 Q15788 1/20 0.45
ALDH1A1 P00352 1/20 0.44
HSP90AA1 P07900 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1726833 0.88 KDM4A (0.60) L3MBTL1KDM4AKDM4BKDM5BKDM5C
SCHEMBL1728489 0.87 KDM4A (0.62) L3MBTL1KDM4AKDM4BKDM5BKDM5C
SCHEMBL1728252 0.79 ADORA3 (0.63) L3MBTL1KDM4AKDM4BKDM5BKDM5C
SCHEMBL1726841 0.78 PHGDH (0.60) LMNASMN1; SMN2NCOA1ALDH1A1
SCHEMBL663003 0.76 L3MBTL1 (0.60) L3MBTL1MITFNPC1LMNASMN1; SMN2
SCHEMBL29978654 0.76 L3MBTL1 (0.60) L3MBTL1MITFNPC1LMNASMN1; SMN2
SCHEMBL1728020 0.75 KMT2A (0.60) LMNASMN1; SMN2USP2ADORA3NCOA1
SCHEMBL1728487 0.73 MEN1 (0.51) LMNASMN1; SMN2MAPK1NCOA1ALDH1A1
SCHEMBL1727760 0.71 MEN1 (0.44) LMNASMN1; SMN2NCOA1ALDH1A1
SCHEMBL21376323 0.69 L3MBTL1 (0.49) L3MBTL1KDM4AKDM4BKDM5BMITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403499-A2 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL Stemsynergy Therapeutics, Inc (US) 2012-01-11 EP disclosed
WO-2010101964-A2 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC (US) 2010-09-10 WO disclosed